-
关于我们
Proji Company was founded in August 2004. It is a high-tech research and development enterprise established by returned overseas students, undertaking the task of industrializing and transforming various scientific research projects. -
Scientific research technology
Scientific research technology
科研技术
Proji Company is a constituent unit of the "National Engineering Research Center for Protein Technology" of Tsinghua University. It is the first national engineering laboratory established by the National Development and Reform Commission at Tsinghua University. Former President of the Chinese Academy of Sciences, Zhou Guangzhao, and the "Father of DNA", Nobel laureate James D. Watson served as honorary directors of the laboratory, with Professor Luo Yongzhang serving as the director. -
Products
公司产品
For nearly two decades, Proji Company has been primarily engaged in the development and production of recombinant protein drugs, antibody drugs, and in-vitro diagnostic reagents. It has established a unique R&D and large-scale preparation technology platform for recombinant protein drugs that has reached international standards. -
Project
项目公司
The company has long received strong support from various levels of government, including the National Development and Reform Commission, the Ministry of Science and Technology, and the municipal governments of Beijing, Yantai, Shenzhen, and Changzhou. -
新闻资讯
The company's marketing network spans 18 provinces and cities across the country (including 6 provinces and cities covered by medical insurance), benefiting more than 4 million patients, and gradually growing into a new benchmark in the biopharmaceutical industry. -
职业发展
From small-scale research institutions to advanced biopharmaceutical bases, the company's marketing network spans 18 provinces and cities across China.
National Engineering Research Center for Protein Technology
The National Engineering Research Center for Protein Technology, established in 2021, formerly known as the National Engineering Laboratory for Anti-tumor Protein Drugs. The center is affiliated with the School of Life Sciences of Tsinghua University, and the director is Professor Luo Yongzhang. The honorary directors are Zhou Guangzhao and James Watson.
The co-construction unit of the center is Protgen Company. The center is committed to developing key core technologies for the industrial preparation of protein drugs. It has pioneered the concept of "young, undamaged, ultra-pure recombinant albumin" internationally and, on this basis, explored from a new perspective the mechanism of "young ultra-pure recombinant albumin" in resisting aging, Alzheimer's disease, Parkinson's disease, type 2 diabetes and several complications, obesity, muscle atrophy, myocardial hypertrophy and other major diseases. The efficacy has been verified in cells and animals. Albumin is the most abundant protein in plasma, accounting for 60% of the total plasma protein and providing 80% of the reducing power in plasma and bearing 80% of the colloid osmotic pressure in plasma. The center is currently researching the scientific mysteries behind these phenomena. "Young ultra-pure recombinant albumin" will be a significant contribution of scientific and technological progress to human civilization, and it will have immeasurable value for the health of the people and the strengthening of the nation, and benefiting humanity.
Beijing Protgen Biotechnology Development Co., Ltd.
Tel:86010- 6297 9258
Postcode: 100085
Email:protgen@protgen.com
Address: No. 32, Chuangye Zhonglu, Haidian District, Beijing
Official Account QR Code
Maintenance Department QR Code
copyright © 2024 Beijing Progen Biotechnology Development Co., Ltd. Powered by：CEglobal TagsFriendly Links:Tsinghua UniversityNEC